Valens Pharma Announces Next Steps
EDMONTON, Aug. 5 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as "CardioMetabolics Inc."), today announced that the Company has suspended work on its DCA i.v program, a proprietary intravenous formulation of dichloroacetate pending further...
Discuss   Add this link to...  Tell a friend   Bury

Comments Who Voted Related Links